Malaysia-based Hovid seeks US FDA nod for tocotrienols


PETALING JAYA: Investors may have overlooked Hovid Bhd’s pharmaceutical business and efforts to register tocotrienols (a type of Vitamin E) as a US Food and Drug Administration (FDA)-approved drug, said CIMB Investment Bank Bhd in a report.

It is currently sold as a dietary supplement under the brand name “Tocovid” but unlike drugs, dietary supplements cannot make the claim of being able to prevent, treat or cure illnesses due to regulatory restrictions.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Business , hovid , drugs

   

Next In Business News

Robust earnings drive Public Bank’s profit optimism
A second chance at SUCC-SEZ
Semiconductor diplomacy key to preserve relevance
Equities pricey, bonds resilient
Finesse in a cuppa
Struggling Tan Chong faces long and rough journey
NEWLY-MINTED LEADERSHIP TEAM
PRIMED FOR PRECISION
Emerging Asia stays steady
European ETFs show promising growth

Others Also Read